Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2024 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Dental Science |
Texto Completo: | https://ojs.ict.unesp.br/index.php/cob/article/view/4172 |
Resumo: | Oral Submucous Fibrosis is a potentially malignant disorder caused by habitual areca nut chewing, which contributes to the dispersion of active alkaloids into subepithelial tissues, stimulating excessive extracellular matrix deposition. Various treatment modalities are available; however, their efficacy in inhibiting fibrosis progression remains limited. Sulforaphane (SFN), an isothiocyanate found abundantly in cruciferous plants, is known to have effective antifibrotic properties. Objective: The present study investigated the antifibrotic effect of SFN via phosphatidylinositol 3 kinase (PI3K), Serine/Threonine Kinase 1 (AKT-1), mammalian target of rapamycin (mTOR) pathway in arecoline (AER) induced fibrosis in human gingival fibroblasts [HGFs]. Material and Methods: MTT assay determined the half-maximal inhibitory concentration of AER and SFN at 24h in the HGF cell line. Expression levels of transforming growth factor B1 (TGFB1), collagen type 1 alpha 2 (COL1A2), hydroxyproline (HYP), PI3, AKT, mTOR, and nuclear factor erythroid 2–related factor 2 (NRF2) were assessed post-AER and SFN treatment using qPCR and western blot analysis. Results: The findings of the study revealed that AER elicited a stimulatory effect, upregulating TGFB1, COL1A2, HYP, PI3K, AKT, and mTOR and downregulating NRF2 expression. Conversely, SFN treatment significantly upregulated NRF2, inhibiting TGFB1 mediated PI3/ AKT/mTOR pathway. Conclusion: These observations suggest that SFN can be used as a promising synergistic antifibrotic agent to combat fibrogenesis via the non-Smad pathway. KEYWORDS Arecoline; NRF2; Oral submucous fibrosis; PI3/AKT/mTOR; Sulforaphane. |
id |
UNESP-20_84fe6f1460ed3c313a87eddfcc25ce5b |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/4172 |
network_acronym_str |
UNESP-20 |
network_name_str |
Brazilian Dental Science |
repository_id_str |
|
spelling |
Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosisOral Submucous Fibrosis is a potentially malignant disorder caused by habitual areca nut chewing, which contributes to the dispersion of active alkaloids into subepithelial tissues, stimulating excessive extracellular matrix deposition. Various treatment modalities are available; however, their efficacy in inhibiting fibrosis progression remains limited. Sulforaphane (SFN), an isothiocyanate found abundantly in cruciferous plants, is known to have effective antifibrotic properties. Objective: The present study investigated the antifibrotic effect of SFN via phosphatidylinositol 3 kinase (PI3K), Serine/Threonine Kinase 1 (AKT-1), mammalian target of rapamycin (mTOR) pathway in arecoline (AER) induced fibrosis in human gingival fibroblasts [HGFs]. Material and Methods: MTT assay determined the half-maximal inhibitory concentration of AER and SFN at 24h in the HGF cell line. Expression levels of transforming growth factor B1 (TGFB1), collagen type 1 alpha 2 (COL1A2), hydroxyproline (HYP), PI3, AKT, mTOR, and nuclear factor erythroid 2–related factor 2 (NRF2) were assessed post-AER and SFN treatment using qPCR and western blot analysis. Results: The findings of the study revealed that AER elicited a stimulatory effect, upregulating TGFB1, COL1A2, HYP, PI3K, AKT, and mTOR and downregulating NRF2 expression. Conversely, SFN treatment significantly upregulated NRF2, inhibiting TGFB1 mediated PI3/ AKT/mTOR pathway. Conclusion: These observations suggest that SFN can be used as a promising synergistic antifibrotic agent to combat fibrogenesis via the non-Smad pathway. KEYWORDS Arecoline; NRF2; Oral submucous fibrosis; PI3/AKT/mTOR; Sulforaphane.Institute of Science and Technology of São José dos Campos2024-04-17info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://ojs.ict.unesp.br/index.php/cob/article/view/417210.4322/bds.2024.e4172Brazilian Dental Science; Vol. 27 No. 1 (2024): Jan - Mar / 2024 - Published Jan 2024Brazilian Dental Science; v. 27 n. 1 (2024): Jan - Mar / 2024 - Published Jan 20242178-6011reponame:Brazilian Dental Scienceinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPenghttps://ojs.ict.unesp.br/index.php/cob/article/view/4172/4714Copyright (c) 2024 Brazilian Dental Scienceinfo:eu-repo/semantics/openAccessAdtani, Pooja NarainSubbarayan , Rajasekaran Shrestha , Rupendra Elsayed , Walid 2024-04-01T17:45:19Zoai:ojs.pkp.sfu.ca:article/4172Revistahttp://bds.ict.unesp.br/PUBhttp://ojs.fosjc.unesp.br/index.php/index/oaisergio@fosjc.unesp.br||sergio@fosjc.unesp.br2178-60112178-6011opendoar:2024-04-01T17:45:19Brazilian Dental Science - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis |
title |
Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis |
spellingShingle |
Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis Adtani, Pooja Narain |
title_short |
Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis |
title_full |
Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis |
title_fullStr |
Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis |
title_full_unstemmed |
Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis |
title_sort |
Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis |
author |
Adtani, Pooja Narain |
author_facet |
Adtani, Pooja Narain Subbarayan , Rajasekaran Shrestha , Rupendra Elsayed , Walid |
author_role |
author |
author2 |
Subbarayan , Rajasekaran Shrestha , Rupendra Elsayed , Walid |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Adtani, Pooja Narain Subbarayan , Rajasekaran Shrestha , Rupendra Elsayed , Walid |
description |
Oral Submucous Fibrosis is a potentially malignant disorder caused by habitual areca nut chewing, which contributes to the dispersion of active alkaloids into subepithelial tissues, stimulating excessive extracellular matrix deposition. Various treatment modalities are available; however, their efficacy in inhibiting fibrosis progression remains limited. Sulforaphane (SFN), an isothiocyanate found abundantly in cruciferous plants, is known to have effective antifibrotic properties. Objective: The present study investigated the antifibrotic effect of SFN via phosphatidylinositol 3 kinase (PI3K), Serine/Threonine Kinase 1 (AKT-1), mammalian target of rapamycin (mTOR) pathway in arecoline (AER) induced fibrosis in human gingival fibroblasts [HGFs]. Material and Methods: MTT assay determined the half-maximal inhibitory concentration of AER and SFN at 24h in the HGF cell line. Expression levels of transforming growth factor B1 (TGFB1), collagen type 1 alpha 2 (COL1A2), hydroxyproline (HYP), PI3, AKT, mTOR, and nuclear factor erythroid 2–related factor 2 (NRF2) were assessed post-AER and SFN treatment using qPCR and western blot analysis. Results: The findings of the study revealed that AER elicited a stimulatory effect, upregulating TGFB1, COL1A2, HYP, PI3K, AKT, and mTOR and downregulating NRF2 expression. Conversely, SFN treatment significantly upregulated NRF2, inhibiting TGFB1 mediated PI3/ AKT/mTOR pathway. Conclusion: These observations suggest that SFN can be used as a promising synergistic antifibrotic agent to combat fibrogenesis via the non-Smad pathway. KEYWORDS Arecoline; NRF2; Oral submucous fibrosis; PI3/AKT/mTOR; Sulforaphane. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-04-17 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://ojs.ict.unesp.br/index.php/cob/article/view/4172 10.4322/bds.2024.e4172 |
url |
https://ojs.ict.unesp.br/index.php/cob/article/view/4172 |
identifier_str_mv |
10.4322/bds.2024.e4172 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://ojs.ict.unesp.br/index.php/cob/article/view/4172/4714 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2024 Brazilian Dental Science info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2024 Brazilian Dental Science |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Institute of Science and Technology of São José dos Campos |
publisher.none.fl_str_mv |
Institute of Science and Technology of São José dos Campos |
dc.source.none.fl_str_mv |
Brazilian Dental Science; Vol. 27 No. 1 (2024): Jan - Mar / 2024 - Published Jan 2024 Brazilian Dental Science; v. 27 n. 1 (2024): Jan - Mar / 2024 - Published Jan 2024 2178-6011 reponame:Brazilian Dental Science instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Brazilian Dental Science |
collection |
Brazilian Dental Science |
repository.name.fl_str_mv |
Brazilian Dental Science - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
sergio@fosjc.unesp.br||sergio@fosjc.unesp.br |
_version_ |
1800214394603307008 |